Macular News

Harvard 2018: Goldis Malek PhD

Goldis Malek, PhD Duke Eye Center Duke University School of Medicine https://dukeeyecenter.duke.edu/research https://pathology.duke.edu/research/s… https://dukeeyecenter.duke.edu/about/… Presentation: Rethinking Nuclear Receptors as Therapeutic Targets for AMD

Harvard 2018: Aparna Lakkaraju PhD

Aparna Lakkaraju, PhD Department of Ophthalmology University of California, San Francisco http://ophthalmology.ucsf.edu/lakkara… Presentation: Intracellular Complement Activation in the Retinal Pigment Epithelium

ARVO 2018: Dr. Felicity de Cogan

EXCLUSIVE INTERVIEW: University of Birmingham Institute of Microbiology and Infection Royal Academy of Engineering Enterprise Fellow Topical treatment for AMD http://www.birmingham.ac.uk/microbiology-infection Presentation: Non-invasive delivery and efficacy of ranibizumab and bevacizumab in rabbit and porcine eyes MacRegen http://www.macregen.com

ARVO 2018: Nathan Hotaling PhD

Nathan Hotaling PhD National Eye Institute Biomaterials Group . Presentation: Training to Improve Precision and Accuracy in the Measurement of Fiber Morphology

ARVO 2018: Sudha Iyengar PhD

Sudha K. Iyengar PhD Professor – Vice Chair for Research Case Western Reserve University http://epbiwww.case.edu/ . Presentation: Identification of genes for Age-Related Macular Degeneration

ARVO 2018: Neena Haider PhD

Neena Haider PhD Associate Professor of Ophthalmology Harvard Medical School Schepens Eye Research Institute Massachusetts Eye and Ear . Presentation: Genetic modifier to ameliorate more than one form of inherited retinal degeneration & Unique genetic models to study the retinal and vascular phenotypes associated with AMD . http://www.masseyeandear.org http://www.schepens.harvard.edu/ http://www.hms.harvard.edu

ARVO 2018: Claus von der Burchard MD

Claus von der Burchard MD Universitatsklinikum Schleswig-Holstein University Eye clinic . Presentation: At Home OCT Scan and monitoring

ARVO 2018: Nanoscope Therapeutics

Nanoscope Therapeutics Samarendra Mohanty, Founder-President Sulagna Bhattacharya, CEO Nanoscope Therapeutics Inc. http://www.nanostherapeutics.com . Presentation: Targeted Gene Therapy

ARVO 2018: Cheryl M Craft PhD

Cheryl M Craft PhD USC Roski Eye Institute Keck Medicine of USC http://eye.keckmedicine.org . Presentation: Understanding how the genes expressed in the eye and pineal gland interact with the environment

ARVO 2018: James Handa MD

James Handa, MD Johns Hopkins Wilmer Eye Institute http://www.hopkinsmedicine.org . Presentation: Identifying pathways that induce vision loss as a consequence of drusen in AMD

ARVO 2018: Margaret DeAngelis PhD

Margaret DeAngelis PhD Moran Eye Center University of Utah School of Medicine https://healthcare.utah.edu/moran/ . Presentation: Genome-Wide Analysis of Allele Specific Expression Demonstrates the Role of Lipid Metabolism in AMD

ARVO 2018: Alauddin Bhuiyan PhD

Alauddin Bhuiyan PhD CEO and Chief Scientist, iHealthScreen Inc. (718) 570-0581 http://www.ihealthscreen.org/ . Presentation: A Prediction Model for Risk of Progression to Late Age-related Macular Degeneration (AMD)

ARVO 2018: Kelly Loyet PhD

Kelly Loyet PhD Senior Scientist – Genentech Presentation: Stability and activity profiles of anti-complement factor D fragments translate across in vitro and in vivo studies to support long-acting delivery approaches

ARVO 2018: Will McGuire

Will McGuire, CEO – Second Sight http://www.secondsight.com/ (818) 833-5000 Presentation: Visual prosthetics

ARVO 2018: Hugh Taylor MD

Hugh Taylor, MD Melbourne School of Population and Global Health The University of Melbourne Genetics of AMD and Macular dystrophies https://mspgh.unimelb.edu.au/ Presentation: Indigenous Eye Health

ARVO 2018: Michael Landowski

Duke University Catherine Bowes Rickman Laboratory Role of complement factor H (CFH) in the pathobiology of AMD Abstract here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795897/

ARVO 2018: Michael Quigley MD

McGill Department of Ophthalmology McGill Academic Eye Centre, Montréal, Québec Presentation: How light damage is implicated in the pathophysiology of Age-Related Macular Degeneration (AMD)

ARVO 2018: Rafal Farjo PhD

Rafal Farjo, PhD Chief Executive Officer EyeCRO http://www.EyeCRO.com (405) 604-8954 Presentation: Creating Models for Research

ARVO 2018: Mitul Mehta MD MS

Clinical Assistant Professor of Vitreoretinal Diseases & Surgery Gavin Herbert Eye Institute University of California, Irvine Eyedaptic: Simulated Natural Vision Eyewear for AMD

ARVO 2018: Thomas Langmann PhD

Professor and Director Chair of Experimental Immunology of the Eye Department of Ophthalmology, University of Cologne Presentation: Innate Immunity as Therapy Target for Retinal Degenerative Diseases

ARVO 2018: Scott McPherson PhD

University of Minnesota, Twin Cities Campus Ophthalmology & Visual Neurosciences Presentation: Imaging Zinc as a Biomarker for Age-Related Macular Degeneration

AAO 2017: Tom Perski

Low Vision Aid Utilizing VR Technology and the Unique Features of Iris Vision http://www.irisvision.com

AAO 2017: Charles Wykoff MD PhD

Charles C. Wykoff, MD, PhD Retina Consultants Houston — New Approaches to Managing Wet Macular Degeneration. Plus, Results of the 6 – Month Prospective, Phase 1/2 HULK Study Regarding Diabetic Macular Edema

AAO 2017: Press Conference

Latest on Gene Therapy and Stem Cell Therapy for Retinal Diseases (Note: Poor Audio) — AAO 2017 Press Conference Nov. 13, 2017 Stephen R. Russell, M.D., University of Iowa Health Care Irene Maumenee, M.D, 2017 Academy Laurate recipient Ninel Z. Gregori, M.D., Bascom Palmer Eye Institute Eyal Banin, M.D., Ph.D …